





























































Zika virus (ZIKV) is a mosquito-borne flavivirus that mostly causes asymptomatic infections or mild 
disease characterized by low-grade fever, rash, conjunctivitis, and malaise. However, the recent 
massive ZIKV epidemics in the Americas have also linked ZIKV infection to fetal malformations like 
microcephaly and Guillain-Barré syndrome in adults, and have uncovered previously unrecognized 
routes of vertical and sexual transmission. Here we describe inhibition of ZIKV replication by suramin, 
originally an anti-parasitic drug, which was more recently shown to inhibit multiple viruses. In cell 
culture-based assays, using reduction of cytopathic effect as read-out, suramin had an EC50 of ~40 
μM and a selectivity index of 48. In single replication cycle experiments, suramin treatment also 
caused a strong dose-dependent decrease in intracellular ZIKV RNA levels and a >3-log reduction in 
infectious progeny titers. Time-of-addition experiments revealed that suramin inhibits a very early step 
of the replication cycle as well as the release of infectious progeny. Only during the first two hours of 
infection suramin treatment strongly reduced the fraction of cells that became infected with ZIKV, 
suggesting the drug affects virus binding/entry. Binding experiments at 4°C using 35S-labeled ZIKV 
demonstrated that suramin interferes with attachment to host cells. When suramin treatment was 
initiated post-entry, viral RNA synthesis was unaffected, while both the release of genomes and the 
infectivity of ZIKV were reduced. This suggests the compound also affects virion biogenesis, possibly 
by interfering with glycosylation and the maturation of ZIKV during its traffic through the secretory 
pathway. The inhibitory effect of suramin on ZIKV attachment and virion biogenesis and its broad-




 Suramin inhibits Zika virus replication in cell culture 
 Suramin interferes with Zika virus attachment to host cells 








1. Introduction  
Zika virus (ZIKV) is a flavivirus that was first isolated in 1947 in Uganda (Dick et al., 1952) and is 
primarily transmitted by Aedes mosquitos. Up to 2007, it received little attention, as only sporadic 
outbreaks were reported and these were not linked to serious disease. ZIKV has gained attention 
after the 2007 outbreak on Yap island and the 2013 epidemic in French Polynesia. Research efforts 
and public concern were further sparked by the massive epidemic in Brazil and many other South- 
and Central-American countries, which uncovered a link between ZIKV infection and serious foetal 
neurodevelopmental defects and neurological complications in adults.  
About 80% of ZIKV infections are asymptomatic. In combination with ZIKV persistence in semen and 
the potential for sexual transmission, this poses a risk to women that are pregnant or trying to 
conceive. Symptomatic ZIKV infections are commonly characterized by low-grade fever, skin rash, 
conjunctivitis, and general malaise. However, the enormous scale of the recent epidemics has also 
revealed uncommon but more serious consequences, like the Guillan-Barré syndrome and foetal 
neurodevelopmental defects, like microcephaly. These could be due to ZIKV’s ability to infect and 
persist in several immune-privileged tissues, like the central nervous system, placenta and testis 
(Miner and Diamond, 2017).  
ZIKV has a 10.7 kb ssRNA genome of positive polarity, which is 5’ capped and lacks a poly(A) tail. 
The replicative cycle begins with binding to receptor and co-receptors, like AXL and TIM1 (Liu et al., 
2016; Meertens et al., 2017), followed by entry through receptor-mediated endocytosis, uncoating and 
translation of the genome into a single polyprotein. The latter is processed by cellular and viral (NS3) 
proteases to yield the structural proteins C, prM and E and 7 nonstructural proteins, which are 
responsible for RNA replication in association with modified endoplasmic reticulum (ER) membranes 
and interactions with the host, including counteracting innate immune responses. Newly synthesized 
genomes, together with C, prM and E, are assembled into immature virions that bud into the ER 
lumen. These pass through the secretory pathway during which prM cleavage by the host protease 
furin leads to maturation, before particles are released into the extracellular space.  
There are no registered vaccines against ZIKV and efforts to identify inhibitors of ZIKV replication 
have been initiated only recently, for example in the form of two large-scale compound screens that 
yielded surprisingly few common hits (Adcock et al., 2017; Barrows et al., 2016; Cheng et al., 2016; 




drug development, it is crucial to identify a large number of ZIKV inhibitors in cell culture and elucidate 
their mode of action, in order to have sufficient lead compounds with the potential to advance further 
towards clinical development.  
Suramin is an approved anti-parasitic drug that also blocks the replication of a variety of viruses (see 
(Albulescu et al., 2015) and references therein), including arboviruses like chikungunya virus (CHIKV) 
(Albulescu et al., 2015; Henss et al., 2016; Ho et al., 2015) and dengue virus (Chen et al., 1997). 
Animal experiments have indicated that suramin can be used for preventing and treating enterovirus-
71 and CHIKV infections (Kuo et al., 2016; Ren et al., 2014). 
In this study we show that suramin effectively blocks ZIKV replication by interfering with attachment, 
while the compound also affects a later step, as it reduces the release of infectious progeny. Our 
results warrant further evaluation of suramin as an anti-ZIKV compound. Its broad spectrum of 
activity, limited toxicity and approved status offer interesting perspectives for repurposing this anti-
parasitic drug as an antiviral.  
 
2. Materials and Methods 
 
2.1. Cells, viruses and compounds 
Vero cells (ATCC CCL-81) were grown in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 8% fetal calf serum (FCS), 100 IU/mL of penicillin and 100 μg/mL of streptomycin 
at 37°C in 5% CO2. ZIKV SL1602 was isolated in Leiden, the Netherlands, in 2016 from an infected 
traveler returning from Suriname (van Boheemen et al, submitted). Vero cells were seeded (150,000 
cells or 75,000 cells/well, respectively) in 12-well or 24-well clusters 24 h prior to infection with ZIKV 
(MOI of 3) in EMEM with 25 mM HEPES, 2% FCS, 2 mM L-glutamine, and antibiotics 
(EMEM/2%FCS). After 2 h, the inoculum was removed, cells were washed 3 times with PBS after 
which they were maintained in EMEM/2%FCS. All experiments with ZIKV were performed in our BSL-
3 facility. Suramin (Sigma) was dissolved in MilliQ to yield a 25 mM stock and mycophenolic acid 







2.2. Cytopathic effect (CPE) reduction assay 
CPE reduction assays with Vero cells were performed by seeding cells at a density of 5,000 cells/well 
in 96-well clusters, 24 h before compound treatment and infection. The next day, 1.5-fold or 2-fold 
serial dilutions of the compound were added to the cells, followed by 500 PFU/well of ZIKV in a total 
volume of 150 µL. Each concentration was tested in quadruplicate and each assay plate contained 
the following controls: no cells, uninfected&untreated cells, infected&untreated cells and 
infected&solvent-treated cells. After 4 days, 30 µL/well of CellTiter 96® Aqueous Non-Radioactive 
Cell Proliferation reagent (Promega) was added. After a 3-h incubation, reactions were stopped and 
virus was inactivated by adding 30 µL of 37% formaldehyde, followed by measuring the absorption at 
490 nm. Viability assays on uninfected cells were performed in parallel to determine the CC50. Data 
were normalized to untreated uninfected cells and EC50 and CC50 values were calculated with Graph-
Pad Prism 7 (see section 2.8). 
 
2.3. ZIKV titration and plaque reduction neutralization titer (PRNT) assay  
Plaque assays were performed as described (Van Boheemen et al, submitted). Briefly, after a 1-min 
centrifugation at 13,000xg, virus-containing cell culture supernatants were 10-fold serially diluted in 
medium and 500-μL volumes were adsorbed for 2 h on confluent Vero cell monolayers in 6-well 
clusters. The inoculum was removed and an overlay of 1.2% Avicel RC-581 (FMC BioPolymer) in 
DMEM, 2% FCS, 25 mM HEPES, and antibiotics, was added. After a 5-day incubation, cells were 
fixed with formaldehyde, stained with crystal violet and plaques were counted. For PRNT, 3.2x104 
PFU of ZIKV were incubated with various dilutions of heat-inactivated patient serum (against ZIKV 
SL1602) or a control serum for 1h at 37°C. Afterwards 250-μL volumes of 10-fold serial dilutions were 
adsorbed for 2 h on confluent Vero cell monolayers in 12-well clusters. An overlay was placed on top 
and plaques were visualized after 5 days as described for the plaque assay.  
 
2.4. ZIKV RNA analysis 
RNA was isolated from ZIKV-infected cells using TriPure isolation reagent (Roche) according to the 
manufacturer’s instructions. ZIKV RNA was isolated from the medium of infected cells using the 
Qiamp Viral mini kit (Qiagen) with AVL lysis buffer spiked with equine arteritis virus (EAV) as internal 
control, as described previously (Scholte et al., 2015). ZIKV RNA copy numbers were determined by 




described (Manuscript in preparation). Briefly, the detection of ZIKV RNA was done with the primer 
pair Fw 5’-AATGGCAGTCAGTGGAGATG/ Rv 5’-ACTCTTGTGTGTCCTTCCTAAC and a FAM-
labelled probe (5’-6FAM-ATAGGTTTGCACATGCCCTCAGGT-3’-BHQ_1) using the TaqMan Fast 
Virus 1-Step Master Mix (Applied Biosystems) and the CFX384 Touch™ Real-Time PCR Detection 
System. Known quantities of in vitro transcribed RNA were used to generate calibration curves for 
absolute quantification of copy numbers. Each sample was analyzed in triplicate. 
 
2.5. Immunofluorescence assay 
Vero cells (50,000 per well) were seeded on coverslips in 24-well clusters. The next day they were 
infected with ZIKV or mock-infected and treated with various concentrations of suramin. At 26 h p.i. 
cells were fixed with 3% paraformaldehyde in PBS, and processed for immunofluorescence 
microscopy as previously described (Scholte et al., 2013). ZIKV-specific proteins were visualized with 
a 1:1000 dilution of the SL1602 patient antiserum, and double-stranded RNA was stained with mouse 
monoclonal antibody J2 (English & Scientific Consulting). Detection of primary antibodies was done 
with 1:500 dilutions of goat anti-human Alexa488 and donkey anti-mouse Cy3. 
 
2.6. Production of 35S-labeled ZIKV and binding assays 
Confluent Vero cells (75 cm2) were infected with ZIKV at an MOI of 0.05 or mock infected and 
incubated for 3 days. Medium was replaced with protein-labeling medium (Met- and Cys-free DMEM) 
containing 88 μCi of 35S-labelled Met and Cys (0.0176 μCi/μL) and cells were incubated for 15 h. The 
culture supernatants were collected and cellular debris was removed by centrifugation for 10 min at 
233 x g. Unincorporated label was removed by pelleting virions through a cushion of 20% sucrose in 
TESV buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, 100 mM NaCl) by ultracentrifugation for 2 h at 
45,000 rpm and 4°C using a Beckmann SW55 rotor. After removal of the supernatant and sucrose 
layer, the virus pellet was washed with TESV buffer, and resuspended in 0.6 mL of TESV. Aliquots of 
labelled virus were stored at -80°C. For binding assays, Vero cells seeded in 24-well clusters were 
incubated with 4 μL (3.2x104 PFU) of radioactive ZIKV for 2 h at 4°C in a total volume of 125 μL. After 
removal of the inoculum and washing three times with PBS, cells were lysed in 200 µL of 100 mM 




using a Beckman-Coulter LS6500 Multi-Purpose scintillation counter and Ultima Gold™ scintillation 
liquid.  
 
2.8. Statistical analysis 
GraphPad Prism 7 was used for EC50, IC50 and CC50 calculations by non-linear regression and for 
statistical analyses by one-way ANOVA with Dunnett’s multiple comparison test.  
 
3. Results  
3.1. Suramin inhibits ZIKV in CPE reduction assays 
To determine the anti-ZIKV activity of compounds, we have set up CPE reduction assays with Vero 
cells, which were treated with serial dilutions of compound, followed by mock-infection or ZIKV-
infection at an MOI of 0.05. After a 4-day incubation, colorimetric viability assays were performed to 
quantify the protective effect of a compound against ZIKV-induced CPE. Publications on compounds 
with demonstrated anti-ZIKV activity were not available at the time we set up our assay (3/2016) and 
therefore we included mycophenolic acid (MPA), known to inhibit a broad-spectrum of viruses, as a 
positive control. MPA had an EC50 of 0.42 μM and a CC50 of over 250 μM in our assay and its antiviral 
effect has also been demonstrated by others ((Adcock et al., 2017; Barrows et al., 2016). Suramin 
protected Vero cells from ZIKV-induced cell death with an EC50 value of 39.8 μM (supplemental Fig. 
S1). The CC50 of suramin was 1.9 mM, resulting in a selectivity index (SI) of 48.  
 
3.2. Suramin reduces ZIKV RNA accumulation and infectious progeny titers in cell culture 
To confirm the antiviral effect of suramin treatment observed in the CPE reduction assays, a dose-
response experiment was performed with ZIKV-infected Vero cells (MOI 3) that were treated with 25 
to 400 μM of suramin (or 2.5 μM MPA as positive control) from 2 h prior to infection up to 44 h p.i. 
Suramin treatment caused a convincing dose-dependent reduction in intracellular ZIKV RNA levels 
(Fig. 1A), yielding a 3-log decrease in ZIKV genome copies after treatment with 400 μM of suramin. 
An even stronger effect was observed on the production of infectious progeny (Fig.1B). No infectious 
particles could be detected at the highest suramin dose tested, although the presence of 40 μM 
residual suramin in the 10-1 dilution of the samples used for titration by plaque assay may have 




Nonetheless, even at 50 μM, suramin treatment caused a more than 2-log reduction in progeny virus 
titers. MPA treatment only modestly inhibited RNA synthesis and virus production, yielding a reduction 
of about 1-log in both assays. 
 
3.3. Suramin inhibits the attachment of ZIKV to host cells  
A time-of-addition experiment was performed to determine which step(s) of the ZIKV replication cycle 
are inhibited by suramin. The compound was added to Vero cells to a final concentration of 200 μM 
either two hours before infection, at the time of infection, or at various time points post infection, after 
which the compound remained present until sample collection at the end of the experiment (Fig. 2). 
Suramin had the strongest inhibitory effect on the accumulation of intracellular ZIKV RNA when added 
prior to or together with the virus (Fig. 2, samples -2 and 0), resulting in a ~100-fold reduction in the 
amount of intracellular ZIKV RNA. When the compound was added 30 min or more after adding the 
virus, the inhibitory effect on the accumulation of intracellular ZIKV RNA diminished rapidly. 
Immunofluorescent staining of ZIKV-infected Vero cells treated with 25-200 µM suramin from 2 h 
before till 2 h after addition of the virus revealed that the compound caused a dose-dependent 
reduction in the number of infected cells reaching 95% at 200 µM (Fig. 3A). The remaining ZIKV-
positive cells appeared not to be protected by suramin treatment as their signal intensity in 
immunofluorescence microscopy resembled that of untreated cells (see inset of Fig. 3A). These 
remaining ZIKV-positive cells are most likely responsible for the residual production of infectious virus 
that was observed when cells were treated with 200 µM suramin from -2 to 2 h p.i. (Fig. 3B). 
Nonetheless, we concluded that suramin treatment during the early steps of the replication cycle 
(binding/entry) only, still resulted in an up to 100-fold and dose-dependent reduction of progeny virus 
titers (at 26 h p.i.).  
To test whether suramin affects ZIKV attachment to host cells, we have produced 35S-labeled ZIKV 
for use in virus binding assays. The radioactive ZIKV was incubated with Vero cells for 2 h at 4°C, 
which should only allow binding, while preventing endocytosis/entry. After washing, cells were lysed 
and the amount of cell-bound radioactivity was determined by scintillation counting. Vero cell-
associated radiolabel was readily detected when 35S-labeled ZIKV was used in this assay, while 
hardly any radiolabel was bound when Vero cells were incubated with a virus-free control sample that 




binding could be measured in this assay, 35S-labeled ZIKV was incubated with a neutralizing 
antiserum from a ZIKV-infected patient prior to the binding assay (Fig. 3C). This serum completely 
neutralized the virus at 1:5 (and higher) dilutions in plaque reduction neutralization assays (Fig. 3C, 
inset). When the binding assay was performed with virus that was neutralized with a 1:5 antiserum 
dilution, a 50% reduction in cell-bound radiolabel was observed. It remains unclear whether the 
remaining amount of radioactivity resulted from cell-bound radiolabeled virus or from radiolabeled 
host proteins that might be absent in the 35S-labeled control sample obtained from mock-infected cells 
as the latter had not undergone the ZIKV-induced CPE. Nonetheless, the assay allowed us to 
measure decreases in ZIKV binding. When various suramin concentrations were tested in this assay, 
we observed a dose-dependent inhibition of 35S-ZIKV binding of up to 50% (Fig. 3D), the same 
residual level of labeling measured when using pre-neutralized virus (Fig. 3C). Taken together these 
results indicate that suramin treatment affects binding of ZIKV to the host cell. 
 
3.4. Suramin treatment also reduces the release of infectious progeny 
Analysis of the infectious virus titers in the supernatant of samples from a time-of-addition experiment 
revealed that suramin not only affected an early step of the replication cycle, but also reduced 
progeny titers when added at later stages (Fig. 4A). When suramin treatment was started at 2 h post 
entry, it had no significant effect on intracellular viral RNA levels, suggesting it does not interfere with 
RNA replication (Fig. 2A), while a ~100-fold reduction of infectious progeny released into the medium 
was observed (Fig. 4A). To confirm that suramin also has a late effect on the release or maturation of 
viral particles, we treated ZIKV-infected cells with 25-200 µM of suramin from 14 to 26 h p.i. As 
expected, the number of infected cells (based on immunofluorescence microscopy) did not change 
(results not shown) by this late suramin treatment, while there was a dose-dependent decrease of up 
to 35-fold in the amount of infectious progeny released (Fig. 4B). 
To further corroborate this effect on virion biogenesis, a time-of-addition experiment was performed, 
in which cells where infected and subsequently treated with 200 µM suramin starting from 2, 14, 18, 
or 22 h p.i. until the medium was harvested at 26 h p.i. A consistent ~10-fold reduction in the amount 
of released genome copies was observed, whether suramin treatment was initiated at 2 h p.i. or as 
late as 22 h p.i. (Fig. 4C, black bars). However a stronger, ~100-fold reduction in released infectious 




latter effect was less pronounced (~10-fold) when suramin treatment was initiated late in the 
replication cycle (18 or 22 h p.i.). These results suggest that suramin affects both the total number of 
released virions (genome copies) and their infectivity (PFU).  
 
4. Discussion  
Here we demonstrate that the approved drug suramin has anti-ZIKV activity by interfering with viral 
attachment, as well as the release of infectious progeny from ZIKV-infected cells. In CPE reduction 
assays suramin had an EC50 value of 39.8 μM and a SI of 48. In this assay, MPA had an EC50 of 0.42 
μM, similar to values reported recently by others (Adcock et al., 2017; Barrows et al., 2016). In low-
MOI CPE reduction assays MPA appeared to inhibit ZIKV more efficiently than suramin, but in the 
context of a high-MOI infection, treatment with 2.5 µM MPA led to a mere 10-fold reduction in the 
accumulation of intracellular ZIKV RNA and infectious ZIKV titers in the medium (Fig. 1). In contrast, 
treatment of cells infected at a high MOI with 50 µM of suramin, while also reducing intracellular ZIKV 
RNA accumulation by 10-fold, yielded a ~300-fold reduction in the amount of infectious progeny (Fig. 
1B). MPA’s limited effect on high-MOI ZIKV infections, its immunosuppressive properties and its 
contraindicated use during pregnancy makes it an unattractive lead to follow. 
Time-of-addition experiments and binding experiments with radioactive 35S-labeled ZIKV at 4°C 
suggested that suramin affects viral attachment to the host cell. 
The inhibition of attachment might be due to suramin’s effect on virions, as was previously reported 
for DENV (Chen et al., 1997) and enterovirus A71 (Nishimura et al., 2015), for which suramin was 
proposed to have a ‘neutralizing effect’ that blocks the interactions of these viruses with cellular 
heparan sulfate, and the P-selectin ligand, respectively. Suramin was suggested to interact with 
surface-exposed positively charged residues in the DENV E protein that are part of the 
glycosaminoglycan-binding (GAG-binding) sites, thereby interfering with attachment to the host cell 
(Chen et al., 1997). It was recently demonstrated that binding to GAGs likely also plays a role in ZIKV 
attachment (Kim et al., 2017).  
Besides interacting with the virion, suramin could also have an effect on host cell (co)receptors, as it 
was shown to abolish the interaction of several cellular receptors with their ligands (Coffey et al., 




the proposed ZIKV receptors AXL (Meertens et al., 2017; Richard et al., 2017) or glycoprotein TIM1 
(Tabata et al., 2016) could interfere with ZIKV attachment.  
Suramin treatment also inhibited the release of infectious progeny from ZIKV-infected cells, not only 
by lowering the number of genomes released, but also by reducing the specific infectivity (Fig. 4). 
This post-entry effect might be due to binding of the negatively charged suramin to one of ZIKV’s 
RNA-binding proteins, as suramin was shown to inhibit Dengue and hepatitis C virus helicase activity 
(Basavannacharya and Vasudevan, 2014; Mukherjee et al., 2012), norovirus RNA-dependent RNA 
polymerase activity (Mastrangelo et al., 2012; Tarantino et al., 2014), reverse transcriptase activity of 
various retroviruses (De Clercq, 1979), including HIV (Chandra et al., 1985), and the activity of 
alphavirus replication complexes (Albulescu et al., 2015). Since we did not observe inhibition of ZIKV 
RNA synthesis in infected cells, an effect on NS5 appears unlikely. Suramin might inhibit the helicase 
activity of ZIKV NS3 or might affect packaging by binding to positively charged residues on the capsid 
protein. This would result in accumulation of genomes in the cell, while virus release would be 
diminished. The E protein, prM, NS1, NS2A, NS4A or/and NS4B (Garcia-Blanco et al., 2016) or furin 
could also be targets of suramin, with consequences for virion assembly, glycosylation of ZIKV 
proteins and/or maturation of the virion, lowering the infectivity of released virions. ZIKV prM, E, and 
NS1 proteins contain potential N-glycosylation sites (Berthet et al., 2014; Kuno and Chang, 2007) and 
glycosylation of the E proteins of ZIKV and West Nile Virus is important for virion maturation and 
infectivity (Li et al., 2006; Mossenta et al., 2017). Suramin is a highly charged molecule that, 
complexed with serum albumin, can be taken up by cells through endocytosis. The concentration of 
albumin determines whether suramin mainly accumulates in the lysosomal compartment or in the 
Golgi apparatus, mitochondria and nucleolus (Baghdiguian et al., 1996). The latter might cause a 
generalized negative effect on the secretory pathway that would also affect virion biogenesis. 
Studies on suramin-related compounds revealed that the six sulfonate groups as well as the 
symmetry of the molecular structure are crucial elements for suramin’s anti-CHIKV activity (Albulescu 
et al., 2015). Addition of sulfonate groups and a higher level of branching increased the compound’s 
anti-enterovirus activity (Nishimura et al., 2015), suggesting the molecule can be further optimized.  
Because of the increased and geographically expanding incidence, unnoticed infections in 
combination with sexual transmission, and potentially severe consequences of mother-to-child 




urgently needed. Suramin has been approved for use in humans and has been used safely and 
successfully in animal models for treating several virus infections. Future studies should evaluate the 
efficacy of suramin on ZIKV replication in animal models and determine whether suramin or related 
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Figure 1. Effect of suramin on the accumulation of intracellular ZIKV RNA and infectious 
progeny titers. A. ZIKV-infected Vero cells were treated with 25 to 400 μM suramin from 2 hours 
prior to infection till 44 h p.i. Untreated and mock-infected cells were included as controls and the 
inhibitory effect of suramin was compared to that of 2.5 μM MPA. Total RNA was isolated from cells 
(n=3) at 44 h p.i. and intracellular ZIKV RNA copy numbers were determined by RT-qPCR using a 
standard curve of in vitro transcribed ZIKV RNA for absolute quantification. B. ZIKV titers in the 
medium of suramin-treated cells (n=3) were determined by plaque assay. Significant differences are 







Figure 2. Effect of suramin on ZIKV replication in time-of-addition assay 
ZIKV-infected Vero cells were treated with 200 μM of suramin starting 2 h before infection until 26 h 
p.i. Untreated (Ut) and mock-infected cells were included as controls. Total RNA was isolated from 
cells at 26 h p.i. and intracellular ZIKV RNA copy numbers were determined by RT-qPCR (n=3). 








Figure 3. Effect of suramin on ZIKV attachment to host cells 
A. ZIKV-infected Vero cells were treated with 25 to 200 μM of suramin, starting 2 hours prior to the 
addition of virus till 2 h p.i. At 26 h p.i. cells were fixed and analyzed by immunofluorescence 
microscopy. Quantification of the percentage of infected cells was performed by determining the 
number of dsRNA (red) and ZIKV protein (green) positive cells in two images acquired per sample. 
Results are presented as the number of infected cells (%) relative to the untreated control. The inset 
shows typical micrographs of untreated cells and cells treated with 200 μM of suramin only during the 
early steps of infection. B. ZIKV titers in the medium of Vero cells that were treated with 25 to 200 μM 
of suramin from -2 to 2 h p.i. Supernatants were harvested at 26 h p.i. from two independent 
infections performed in duplicate, and ZIKV titers were determined by plaque assay (2 replicates per 
supernatant). C. ZIKV binding assay. 35S-labeled ZIKV was incubated with Vero cells for 2 h at 4°C. A 
virus-free control sample that had been prepared by 35S-labeling of mock-infected cells was included 
as a negative control (Mock). 35S-labeled ZIKV that was neutralized (ZIKV/Neu) with a patient immune 
serum (see inset for PRNT results) was included as a control for reduced binding. After extensive 
washing the remaining cell-bound radioactivity was quantified by scintillation counting (n=2). D. Effect 
of suramin on ZIKV binding. 35S-labeled ZIKV was incubated for 2 h at 4°C with Vero cells without 
suramin or in the presence of 12.5 to 100 μM suramin. After extensive washing the remaining cell-
bound radioactivity was quantified by scintillation counting (n=2). Significant differences compared to 







Figure 4. Effect of suramin on the production of infectious ZIKV progeny 
A. Time-of-addition-assay. ZIKV-infected Vero cells were treated with 200 μM of suramin from -2 to 
26 h p.i. Untreated (Ut) and mock-infected cells were included as controls. At 26 h p.i. supernatants 
were harvested in triplicate and virus titers were determined by plaque assay. B. ZIKV-infected Vero 
cells were treated with 25 to 200 μM suramin from 14 to 26 h p.i. Untreated and mock-infected cells 
were included as controls. At 26 h p.i., supernatants were harvested from two independent infections 
performed in duplicate and analyzed by plaque assay (n=4). C. ZIKV-infected Vero cells were treated 
with 200 μM of suramin starting at 2, 14, 18, and 22 h p.i. Untreated (Ut) and mock-infected cells were 
included as controls. At 26 h p.i., supernatants were harvested and virus titers were analyzed by 
plaque assay (n=3). Viral RNA was isolated from the supernatants and copy numbers were 
determined by RT-qPCR (n=3). Significant differences compared to untreated infected cells are 
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